Nathan Evans, Sarah J. Gascoigne, Guillermo M. Besne, Chris Thornton, Gabrielle M. Schroeder, Fahmida A Chowdhury, Beate Diehl, John S Duncan, Andrew W McEvoy, Anna Miserocchi, Jane de Tisi, Peter N. Taylor, Yujiang Wang
{"title":"Anti-seizure medication load is not correlated with early termination of seizure spread","authors":"Nathan Evans, Sarah J. Gascoigne, Guillermo M. Besne, Chris Thornton, Gabrielle M. Schroeder, Fahmida A Chowdhury, Beate Diehl, John S Duncan, Andrew W McEvoy, Anna Miserocchi, Jane de Tisi, Peter N. Taylor, Yujiang Wang","doi":"arxiv-2409.01767","DOIUrl":null,"url":null,"abstract":"Anti-seizure medications (ASMs) are the mainstay of treatment for epilepsy,\nyet their effect on seizure spread is not fully understood. Higher ASM doses\nhave been associated with shorter and less severe seizures. Our objective was\nto test if this effect was due to limiting seizure spread through early\ntermination of otherwise unchanged seizures. We retrospectively examined intracranial EEG (iEEG) recordings in 15 subjects\nthat underwent ASM tapering during pre-surgical monitoring. We estimated ASM\nplasma concentrations based on pharmaco-kinetic modelling. In each subject, we\nidentified seizures that followed the same onset and initial spread patterns,\nbut some seizures terminated early (truncated seizures), and other seizures\ncontinued to spread (continuing seizures). We compared ASM concentrations at\nthe times of truncated seizures and continuing seizures. We found no substantial difference between ASM concentrations when truncated\nvs. continuing seizures occurred (Mean difference = 4%, sd = 29%, p=0.6). Our results indicate that ASM did not appear to halt established seizures in\nthis cohort. Further research is needed to understand how ASM may modulate\nseizure duration and severity.","PeriodicalId":501517,"journal":{"name":"arXiv - QuanBio - Neurons and Cognition","volume":"125 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"arXiv - QuanBio - Neurons and Cognition","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/arxiv-2409.01767","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Anti-seizure medications (ASMs) are the mainstay of treatment for epilepsy,
yet their effect on seizure spread is not fully understood. Higher ASM doses
have been associated with shorter and less severe seizures. Our objective was
to test if this effect was due to limiting seizure spread through early
termination of otherwise unchanged seizures. We retrospectively examined intracranial EEG (iEEG) recordings in 15 subjects
that underwent ASM tapering during pre-surgical monitoring. We estimated ASM
plasma concentrations based on pharmaco-kinetic modelling. In each subject, we
identified seizures that followed the same onset and initial spread patterns,
but some seizures terminated early (truncated seizures), and other seizures
continued to spread (continuing seizures). We compared ASM concentrations at
the times of truncated seizures and continuing seizures. We found no substantial difference between ASM concentrations when truncated
vs. continuing seizures occurred (Mean difference = 4%, sd = 29%, p=0.6). Our results indicate that ASM did not appear to halt established seizures in
this cohort. Further research is needed to understand how ASM may modulate
seizure duration and severity.